UNSPSC 51162730: Nesosteine

This classification denotes a mucolytic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 445J9K442Z. European Medicines Agency schedules Nesosteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09208MIG. Nesosteine generally arises in the molecular formula C11H11NO3S.

UNSPSC 51162730 Nesosteine, a Commodity code, covers pharmaceutical and medical products that state and local governments procure for public health and community health initiatives, though recent solicitations under this code tag demonstrate a wider pharmaceutical procurement scope than the code's nominal name suggests. The work being solicited includes naloxone acquisition for opioid overdose response, safe drug deactivation systems, and participation in multi-source generic pharmaceutical and over-the-counter product supply agreements serving state and local health facilities. Issuing bodies include county health departments and state cooperative purchasing alliances; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, appear as recent solicitors, with MMCAP's scope extending to participating state and local government facilities across multiple states including Oregon.

Activity under the code spans Florida and the Upper Midwest, with at least one documented multi-state cooperative vehicle. A representative recent opportunity is Seminole County's IFB 60459723LAS (due July 26, 2023), which sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a two-year initial term and one-year renewal option and compliance requirements including E-Verify, drug-free workplace certification, and federal clean air and water pollution control adherence. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co., LLC), maintain cGMP and Drug Supply Chain Security Act compliance, and accept a 3 percent administrative fee, with evaluation weighted 75 percent on price competitiveness and 25 percent on fixed pricing, administrative compliance, EDI capability, and fee acceptance.